drugset
drugset / Trial / NCT01011556

A Study for the Transdermal Application of Teriparatide

NCT01011556 ↗

Phase 2 Completed 233 enrolled Eli Lilly and Company TransPharma Medical · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of this study is to help answer the following research questions: 1. How teriparatide given using a skin patch (transferred through the skin using the ViaDerm Teriparatide System) compares to teriparatide injected under the skin with a needle (pen injector) affects your bone density (how solid or porous your bones are). 2. The safety of the teriparatide skin patch and any side effects that might be associated with it.

Timeline

Start
2009-11
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous
Comparator Teriparatide Protein / enzyme biologic 30 ug Subcutaneous
Comparator Teriparatide Protein / enzyme biologic 50 ug Subcutaneous
Comparator Teriparatide Protein / enzyme biologic 80 ug Subcutaneous

Indications

osteoporosis